| scholarly article | Q13442814 |
| P356 | DOI | 10.3233/BD-1999-11109 |
| P698 | PubMed publication ID | 15687596 |
| P2093 | author name string | M X Sliwkowski | |
| P Carter | |||
| B M Fendly | |||
| G D Lewis | |||
| P304 | page(s) | 103-111 | |
| P577 | publication date | 2000-01-01 | |
| P1433 | published in | Breast Disease | Q15750960 |
| P1476 | title | Development of herceptin | |
| P478 | volume | 11 |
| Q77958509 | A new RNase-based immunoconjugate selectively cytotoxic for ErbB2-overexpressing cells |
| Q28207289 | An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors |
| Q55647210 | Chromoanasynthesis is a common mechanism that leads to ERBB2 amplifications in a cohort of early stage HER2+ breast cancer samples. |
| Q37250084 | Crystallization and preliminary crystallographic studies of the single-chain variable fragment of antibody chA21 in complex with an N-terminal fragment of ErbB2. |
| Q100512363 | Direct stimulation of ERBB2 highlights a novel cytostatic signaling pathway driven by the receptor Thr701 phosphorylation |
| Q37234153 | Dynamic analysis of the epidermal growth factor (EGF) receptor-ErbB2-ErbB3 protein network by luciferase fragment complementation imaging |
| Q34314489 | Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex |
| Q40316579 | Molecular modeling of nearly full-length ErbB2 receptor. |
| Q37777992 | Pursuit of Personalized Anticancer Therapy: Leveraging Collaboration Between Academia and the Biotech/Pharmaceutical Industry |
| Q73046119 | Ready to partner |
| Q34532338 | Reorienting the Fab domains of trastuzumab results in potent HER2 activators |
| Q35764163 | Stability engineering of anti-EGFR scFv antibodies by rational design of a lambda-to-kappa swap of the VL framework using a structure-guided approach |
| Q42797006 | Trastuzumab (Herceptin ® ): Overcoming Resistance in HER2 -Overexpressing Breast Cancer Models |
Search more.